Abstract
Measurement of striatal volume using magnetic resonance imaging (MRI) provides a marker of striatal degeneration in Huntington disease (HD). Recent evidence suggests that diffusion-weighted MRI (DWI) may also detect striatal damage in HD. Here, we compared the sensitivities of volumetric MRI and DWI at distinguishing 10 patients with early symptomatic HD from 12 agematched controls. Additionally, we assessed longitudinal changes in striatal volume and diffusivity in 8 of the HD patients over a 2-year period. At baseline, HD patients had significantly smaller volumes and significantly higher trace of the diffusion coefficient (Trace(D)) values of putamen and caudate than controls, but the volume differences were relatively larger than the Trace(D) differences. Putaminal and caudate volumes were outside the normal range in 9 of 10 HD patients, whereas Trace(D) values of putamen and caudate were abnormal in 8 and 6 of 10 HD subjects, respectively. During 2-year follow-up, there was significant volume loss of HD putamen (mean change: –8.0 %) and caudate (mean change: –12.7 %). By contrast, longitudinal Trace(D) changes of putamen (mean change: 4.0 %) and caudate (mean change: 3.8 %) did not reach statistical significance. Thus, volumetric MRI seems more sensitive to striatal degeneration in early symptomatic HD than DWI.
Similar content being viewed by others
References
Aylward EH (2007) Changes in MRIstriatal volumes as a biomarker inpreclinical Huntington’s disease. BrainRes Bull 72:152–158
Aylward EH, Li Q, Stine OC, Ranen N,Sherr M, Barta PE, Bylsma FW, PearlsonGD, Ross CA (1997) Longitudinalchange in basal ganglia volume inpatients with Huntington’s disease.Neurology 48:394–399
Aylward EH, Sparks BF, Field KM,Yallapragada V, Shpritz BD, RosenblattA, Brandt J, Gourley LM, Liang K, ZhouH, Margolis RL, Ross CA (2004) Onsetand rate of striatal atrophy in preclinicalHuntington disease. Neurology 63:66–72
Demaerel P, Baert AL, VanopdenboschL, Robberecht W, Dom R (1997) Diffusion-weighted magnetic resonanceimaging in Creutzfeldt-Jakob disease.Lancet 349:847–848
Helenius J, Soinne L, Perkiö J, SalonenO, Kangasmäki A, Kaste M, Carano RA,Aronen HJ, Tatlisumak T (2002) Diffusion-weighted MR imaging in normalhuman brains in various age groups.Am J Neuroradiol 23:194–199
Kassubek J, Juengling FD, Kioschies T,Henkel K, Karitzky J, Kramer B, EckerD, Andrich J, Saft C, Kraus P, AschoffAJ, Ludolph AC, Landwehrmeyer GB(2002) Topography of cerebral atrophyin early Huntington’s disease: a voxelbased morphometric MRI study.J Neurol Neurosurg Psychiatry 75:213–220
Kruit MC, van Buchem MA, HofmanPA, Bakkers JT, Terwindt GM, FerrariMD, Launer LJ (2004) Migraine as arisk factor for subclinical brain lesions.JAMA 291:427–434
Maes F, Collignon A, Vandermeulen D,Marchal G, Suetens P (1997) Multimodalityimage registration by maximizationof mutual information. IEEETrans Med Imaging 16:187–198
Mascalchi M, Lolli F, Della Nave R,Tessa C, Petralli R, Gavazzi C, Politi LS,Macucci M, Filippi M, Piacentini S(2004) Huntington disease: volumetric,diffusion-weighted, and magnetizationtransfer MR imaging of brain. Radiology232:867–873
Rosas HD, Tuch DS, Hevelone ND,Zaleta AK, Vangel M, Hersch SM, SalatDH (2006) Diffusion tensor imaging inpresymptomatic and early Huntington’sdisease: selective white matterpathology and its relationship to clinicalmeasures. Mov Disord 9:1317–1325
Ruocco HH, Bonilha L, Li LM, Lopes-Cendes I, Cendes F (2008) Longitudinalanalysis of regional grey matterloss in Huntington disease: effects ofthe length of the expanded CAG repeat.J Neurol Neurosurg Psychiatry79:130–135
Seppi K, Schocke MF, Esterhammer R,Kremser C, Brenneis C, Mueller J,Boesch S, Jaschke W, Poewe W,Wenning GK (2003) Diffusion-weightedimaging discriminatesprogressive supranuclear palsy fromPD, but not from the parkinson variantof multiple system atrophy. Neurology60:922–927
Seppi K, Schocke MFH, Mair KJ, EsterhammerR, Weirich-Schwaiger H, UtermannB, Egger K, Brenneis C, GranataR, Boesch S, Poewe W, Wenning GK(2006) Diffusion-weighted imaging inHuntington’s disease. Mov Disord 21:1043–1047
The Huntington’s Disease CollaborativeResearch Group (1993) A novelgene containing a trinucleotide repeatthat is expanded and unstable onHuntington’s disease chromosomes.Cell 72:971–983
The Huntington Study Group (1996)Unified Huntington’s Disease RatingScale: reliability and consistency. MovDisord 11:136–142
Thieben MJ, Duggins AJ, Good CD,Gomes L, Mahant N, Richards F,McCusker E, Frackowiak RSJ (2002)The distribution of structural neuropathologyin pre-clinical Huntington’sdisease. Brain 125:1815–1828
Van Leemput K, Maes F, VandermeulenD, Suetens P (1999) Automated model-basedtissue classification of MRimages of the brain. IEEE Trans MedImaging 18:897–908
Van Oostrom JC, Maguire RP, Verschuuren-Bemelmans CC, Veenma-van derDuin L, Pruim J, Roos RA, Leenders KL(2005) Striatal dopamine D2 receptors,metabolism, and volume in preclinicalHuntington disease. Neurology 65:941–943
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vandenberghe, W., Demaerel, P., Dom, R. et al. Diffusion-weighted versus volumetric imaging of the striatum in early symptomatic Huntington disease. J Neurol 256, 109–114 (2009). https://doi.org/10.1007/s00415-009-0086-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-009-0086-0